What is Alpha-Gal Syndrome?

Alpha-Gal Syndrome (AGS) is an allergic condition triggered by the bite of a Lone Star tick. It causes allergic reactions to galactose-alpha-1,3-galactose (alpha-gal), a sugar molecule found in most mammals. Symptoms typically appear 3-6 hours after eating red meat, pork, or lamb, and can range from hives to life-threatening anaphylaxis. According to the CDC, over 450,000 Americans may have developed AGS since 2010.

What foods should Alpha-Gal patients avoid?

Alpha-Gal patients must avoid all mammalian meat including beef, pork, lamb, venison, and bison. Many also react to mammalian by-products like gelatin (found in gummy vitamins and gel capsules), dairy products, and ingredients derived from mammals such as lard, tallow, and carrageenan. Safe alternatives include poultry (chicken, turkey, duck), fish, seafood, eggs, and all plant-based foods.

What medications are safe for Alpha-Gal Syndrome?

Many medications contain hidden mammalian ingredients. Gel capsules and softgels often contain bovine or porcine gelatin. Safe alternatives include tablets, caplets, liquids, and capsules made with vegetable-based HPMC. Always check inactive ingredients for gelatin, magnesium stearate (usually plant-derived in US), lactose, and stearic acid. VectorShield helps patients identify safe medication alternatives.

What are the 4 sensitivity levels of Alpha-Gal Syndrome?

Alpha-Gal sensitivity varies by patient: Level 1 (Mild, ~40%) - react only to mammalian meat; Level 2 (Moderate, ~30%) - also react to gelatin products; Level 3 (Significant, ~20%) - also react to dairy products; Level 4 (Severe, ~10%) - react to trace amounts and cross-contamination, sometimes called 'super reactors'. Sensitivity can change over time, especially with additional tick bites.

Can Alpha-Gal Syndrome be cured?

There is currently no cure for Alpha-Gal Syndrome, but many patients see improvement over time if they avoid additional tick bites. Some patients report tolerance returning after 1-5 years of strict avoidance and no new tick exposures. However, a single new tick bite can restart or worsen the condition. Management focuses on strict avoidance of trigger foods and carrying emergency medication like epinephrine.

CDC SourceContent informed by CDC Alpha-Gal Syndrome resourcesView CDC resources →

Research & News

Alpha-Gal Research

Stay updated on the latest scientific developments, CDC updates, and research publications about Alpha-Gal Syndrome.

Key Publications

Foundational and recent research on Alpha-Gal Syndrome

The evolving story of alpha-gal syndrome

2023

Platts-Mills TAE, Commins SP, Biedermann T, et al.

Comprehensive review of AGS pathophysiology, epidemiology, and clinical management strategies.

J Allergy Clin ImmunolPubMed: 37116679

Alpha-gal syndrome: An emerging cause of food allergy in the United States

2023

Thompson JM, Carpenter A, Kersh GJ, et al.

CDC report on geographic distribution and estimated prevalence of AGS in the United States.

MMWR Morb Mortal Wkly RepPubMed: 37498790

Galactose-alpha-1,3-galactose-specific IgE is associated with anaphylaxis but not asthma

2009

Commins SP, Satinover SM, Hosen J, et al.

Landmark study establishing the link between alpha-gal IgE and delayed anaphylaxis to red meat.

Am J Respir Crit Care MedPubMed: 19286626

Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose

2009

Commins SP, Platts-Mills TA

Original characterization of AGS clinical presentation and diagnostic approach.

J Allergy Clin ImmunolPubMed: 19070355

Tick bites and red meat allergy

2011

Commins SP, James HR, Kelly LA, et al.

Establishing the causal link between tick bites and development of alpha-gal sensitivity.

Curr Opin Allergy Clin ImmunolPubMed: 21772139

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

2008

Chung CH, Mirakhur B, Chan E, et al.

Initial discovery linking alpha-gal IgE to severe reactions to cetuximab in cancer patients.

N Engl J MedPubMed: 18322263

Search PubMed for More

Active Clinical Trials

Researchers are actively studying new diagnostic tools, treatments, and desensitization approaches for AGS.

Browse AGS Trials Recruiting Only

Research Areas

Epidemiology

Geographic distribution, prevalence estimates, and demographic patterns

alpha-gal prevalence alpha-gal epidemiology lone star tick distribution

Pathophysiology

Mechanisms of sensitization, IgE response, and delayed reaction pathways

alpha-gal mechanism alpha-gal IgE tick saliva alpha-gal

Diagnosis

Testing methods, sensitivity/specificity, and diagnostic algorithms

alpha-gal diagnosis alpha-gal sIgE test alpha-gal skin prick

Treatment

Management strategies, immunotherapy research, and prognosis studies

alpha-gal treatment alpha-gal immunotherapy alpha-gal desensitization

CDC Resources

Official CDC pages on Alpha-Gal Syndrome

Alpha-Gal Syndrome Home About AGS Signs & Symptoms Managing AGS Clinical Diagnosis & Testing Provider Training Products Containing Alpha-Gal

We monitor these CDC pages for updates. Content on this site reflects the latest CDC guidance as of our last sync.

Are You a Researcher?

If you're conducting research on Alpha-Gal Syndrome and would like your work featured here, or if you have corrections to existing content, please reach out.

Alpha-Gal Research

Recent News & Updates

CDC Releases First National AGS Prevalence Estimates

Geographic Distribution of Alpha-Gal Cases Mapped

Free CDC Training Course Launched

Key Publications

Active Clinical Trials

Research Areas

CDC Resources

Are You a Researcher?